Form 4: Hims & Hers Chief Commercial Officer Executes Pre-Planned Stock Option Exercises and Sales

Hims & Hers Health, Inc.'s Chief Commercial Officer, Michael Chi, engaged in pre-planned transactions, exercising stock options and selling an equivalent number of Class A Common Stock shares.

Summary

• Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (HIMS), executed transactions on July 23, 2025, and July 24, 2025.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2025.
• On July 23, 2025, Chi exercised options to acquire a total of 13,750 shares of Class A Common Stock at exercise prices of $5.01 (12,600 shares), $6.82 (900 shares), and $11.53 (250 shares).
• On the same day, Chi disposed of 13,750 shares of Class A Common Stock at a price of $56.00 per share.
• On July 24, 2025, Chi exercised options to acquire 2,100 shares of Class A Common Stock at an exercise price of $5.01.
• Also on July 24, 2025, Chi disposed of 2,100 shares of Class A Common Stock at a price of $57.52 per share.
• Following these transactions, Michael Chi's direct beneficial ownership of Class A Common Stock is 278,654 shares.
• Remaining derivative securities (stock options) beneficially owned total 561,952, with various exercise prices and vesting schedules.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transactions are pre-planned under a Rule 10b5-1 plan, indicating a routine monetization of vested equity rather than a reaction to new company-specific information. The number of shares acquired through exercise exactly matches the number of shares sold, suggesting a 'sell-to-cover' or 'cashless exercise' strategy for tax and liquidity purposes, not a significant reduction in overall exposure.

Positives

• The transactions represent the monetization of vested stock options by a key executive, indicating the realization of value from their equity compensation.
• The sales were executed at significantly higher market prices ($56.00 and $57.52) compared to the option exercise prices ($5.01, $6.82, $11.53), demonstrating substantial gains for the reporting person.

Negatives

• The sale of shares by a Chief Commercial Officer, even if pre-planned, results in a reduction of their direct equity stake in the company, which some investors might interpret as a lack of increased conviction.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details routine insider trading activity under a pre-arranged plan, which is common for executives to manage their equity compensation and liquidity. It does not provide insights into broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: The transactions represent a change in the direct beneficial ownership of Class A Common Stock by a key executive. While the sales were pre-planned, they slightly reduce the executive's direct equity stake, which could be viewed neutrally or with slight caution by some investors.

Key Dates

Keywords

Hims & Hers Health, HIMS, SEC Form 4, Insider Trading, Stock Options, Equity Compensation, Rule 10b5-1 Plan, Michael Chi, Chief Commercial Officer